Breast Cancer : Targets and Therapy最新文献

{"title":"Plasma Vitamin C Levels in Distinguishing Benign from Malignant Breast Tumors and Clinical Correlates in Chinese Patients: A Cross-Sectional Study.","authors":"Shuai Jiang, Dongqing Gao, Yichuang Yin, Zhonghua Sun, Tingting Ding, Ying He, Yifei Zhang, Yuexin Li, Mei Dong","doi":"10.2147/BCTT.S579640","DOIUrl":"10.2147/BCTT.S579640","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common malignancy in women globally, with rising incidence and earlier onset. Vitamin C, an essential micronutrient, plays critical roles in immune regulation and antioxidation, and cancer patients often exhibit lower plasma levels.</p><p><strong>Aim: </strong>To assess plasma vitamin C as a predictive biomarker for breast cancer and its clinical relevance.</p><p><strong>Methods: </strong>From January to July 2025, 115 patients with benign breast tumors and 131 breast cancer patients were enrolled. Inclusion criteria were age >18 years and no regular vitamin C supplementation in the prior three months. Exclusion criteria included recent high-dose vitamin C supplementation and pregnancy. Fasting blood samples were collected prior to surgery for benign tumor patients, and 21 days after discharge (immediately before the next chemotherapy cycle) for breast cancer patients. Plasma vitamin C concentrations were quantified using UPLC-MS/MS. Clinical data, including demographics, tumor characteristics, and treatment-related parameters, were recorded. Statistical analyses were performed using SPSS 27.0.</p><p><strong>Results: </strong>Plasma vitamin C concentrations were significantly lower in breast cancer patients (median 0.72 μg/mL) compared to benign tumor patients (mean 4.06 μg/mL). In benign patients, vitamin C levels negatively correlated with BMI. In breast cancer patients, vitamin C levels were significantly associated with TNM stage, pathological type, and number of metastatic sites. Hematocrit, platelet distribution width, triglycerides, and hemoglobin significantly correlated with plasma vitamin C levels. Patients receiving anthracycline-based chemotherapy had the lowest vitamin C levels, and severe adverse effects (grade ≥3) were linked to further reductions.</p><p><strong>Conclusion: </strong>Plasma vitamin C levels are significantly lower in breast cancer patients than in benign tumor cases, correlating with disease severity, chemotherapy regimens, and adverse effects. Our findings identify plasma vitamin C as a potential dual-utility biomarker for distinguishing malignant tumors and predicting chemotherapy-related toxicity, suggesting its therapeutic potential as a nutritional modulator.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"579640"},"PeriodicalIF":3.6,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148142684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices.","authors":"Sharif Kullab, Ahmed Refae, Abdullah Altwairgi, Atlal Abusanad, Shereef Elsamany, Nafisa A Abdelhafiez, Bassam Basulaiman, Amer Zahralliyali, Abdulraheem Ahmed Alshangiti, Mustafa Al-Mubarak, Ahmed Alwbari, Aisha Alharbi, Ahmed Osman, Hesham Kiwan, Sabah Alaklabi","doi":"10.2147/BCTT.S599184","DOIUrl":"10.2147/BCTT.S599184","url":null,"abstract":"<p><strong>Purpose: </strong>New therapies can improve outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC), including those with brain metastases (BMs). To our knowledge this is the first review focusing on HER2+ mBC, with and without BMs, in the Saudi Arabian context. This review evaluated the epidemiology of HER2+ mBC with and without BMs, treatment and monitoring practices in Saudi Arabia.</p><p><strong>Methods: </strong>Two key strategies have been pursued: a comprehensive literature review of international recommendations to complement a focused, nationally-representative cross-sectional survey involving BC experts in Saudi Arabia using an 18-item questionnaire.</p><p><strong>Results: </strong>Twelve expert BC physicians from tertiary treatment centers in Saudi Arabia completed the survey. It was estimated that 15-35% of mBC patients present with HER2+ disease, with 5-25% developing BMs. Internationally, brain imaging of asymptomatic patients is currently a subject of controversial debate; only 17% of surveyed physicians conducted brain imaging in asymptomatic patients. Treatment of HER2+ mBC with and without BMs in Saudi Arabia largely aligned with international recommendations identified in our literature analysis, although access to lapatinib, tucatinib and neratinib can be limited and may lead to use of alternative regimens. In third-line or later settings, tucatinib combinations were favored by physicians.</p><p><strong>Conclusion: </strong>The management of HER2+ mBC with and without BMs among expert physicians in Saudi Arabia is aligned with international guidelines. The tucatinib-combination may be considered the standard of care for adult patients with HER2+ locally advanced or mBC who have received at least two prior anti-HER2+ treatment regimens, including patients with BMs. Ensuring access to innovative HER2+ mBC therapies across Saudi Arabia is crucial to supporting best practice.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"599184"},"PeriodicalIF":3.6,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148142663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization and Cytotoxicity of West Java Coffee Extracts, Chlorogenic Acid, Caffeine on MDA-MB-231, MCF-7 Cell Lines, and Their Impact on <i>MYC</i> and <i>AXIN2</i> Wnt Pathway Gene Expression.","authors":"Mohamed Aborziza, Ade Zuhrotun, Agung Novianto, Riezki Amalia, Taufik Muhammad Fakih, Muchtaridi Muchtaridi","doi":"10.2147/BCTT.S606305","DOIUrl":"10.2147/BCTT.S606305","url":null,"abstract":"<p><strong>Background: </strong>Coffee bean extracts have been widely investigated for their potential anticancer properties, particularly due to bioactive compounds such as chlorogenic acid and caffeine. Breast cancer development involves complex genetic and signaling alterations, including dysregulation of the Wnt/β-catenin pathway.</p><p><strong>Purpose: </strong>To determine the phytochemical composition and quantify caffeine and chlorogenic acid in West Java coffee bean extracts. The study assessed their effects on the viability of MDA-MB-231 and MCF-7 breast cancer cells, and examined impacts on the Wnt pathway, focusing on <i>MYC</i> and <i>AXIN2</i> expression.</p><p><strong>Methods: </strong>Phytochemical screening and HPLC analysis are used to measure chlorogenic acid and caffeine in green and roasted coffee extracts. Cytotoxic activity and IC₅ ₀ values in MDA-MB-231 and MCF-7 breast cancer cells were assessed with the WST-8 assay. Gene expression of <i>MYC</i> and <i>AXIN2</i> was analyzed by q-RT-PCR to assess modulation of the Wnt pathway. Cytotoxic selectivity was tested in HEK293 cells. Flow cytometry analyzes apoptosis and the cell cycle. Molecular mechanisms were explored using docking, 200-ns molecular dynamics simulations, and MM-PBSA binding free energy calculations targeting Tankyrase-1 and Estrogen Receptor Alpha.</p><p><strong>Results: </strong>Roasting and extraction methods affected phytochemicals, with higher temperatures reducing chlorogenic acid levels. Coffee extracts showed cytotoxicity against MDA-MB-231 (IC₅ ₀ 258.4-637 µg/mL) and MCF-7 (IC₅ ₀ 190.7-686 µg/mL) cells, and minimal toxicity to HEK293 cells-Green Arabica and Robusta extracts, via maceration, notably downregulated <i>MYC</i> and slightly reduced <i>AXIN2</i>. Flow cytometry indicated increased late apoptosis and cell-cycle arrest. Docking analysis found that chlorogenic acid binds more strongly to Tankyrase-1 than ERα. MD and MM-PBSA confirmed stable, energetically favorable binding to Tankyrase-1 complex.</p><p><strong>Conclusion: </strong>Coffee bean extracts, especially chlorogenic acid-rich green coffee, show selective antiproliferative effects in breast cancer cells and may act through Wnt signaling rather than estrogen receptors. More in vivo and mechanistic studies are needed to confirm their potential as complementary or preventive anticancer agents.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"606305"},"PeriodicalIF":3.6,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148136377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiation of Benign and Malignant BI-RADS 4-5 Breast Lesions Using Ultrasound Localization Microscopy-Derived Microvascular Biomarkers: A Prospective Study.","authors":"Wei Wei, Wenwu Lu, Wang Zhou, Di Zhang, Xiangyi Xu, Ji Zhou, Yuanyuan Gao, Yayang Duan, Chaoxue Zhang","doi":"10.2147/BCTT.S596312","DOIUrl":"10.2147/BCTT.S596312","url":null,"abstract":"<p><strong>Objective: </strong>To investigate qualitative and quantitative microvascular biomarkers derived from ultrasound localization microscopy (ULM) for differentiating benign and malignant breast lesions, and to evaluate their added value in improving BI-RADS-based diagnosis.</p><p><strong>Methods: </strong>In this prospective study, 295 patients with 301 breast lesions classified as BI-RADS category 4-5 on conventional ultrasound (US) underwent contrast-enhanced ultrasound and ULM prior to surgery or biopsy. Qualitative vascular biomarkers and quantitative parameters were derived from ULM images. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. BI-RADS categories were further re-evaluated by integrating ULM-derived biomarkers.</p><p><strong>Results: </strong>ULM qualitative vascular biomarkers classified microvascular morphology into five patterns: avascular, dot-strip, circular, chaotic, and radial. Benign lesions predominantly exhibited avascular, dot-strip, and circular patterns (5.6%, 23.4%, and 48.6%, respectively), whereas malignant lesions were mainly characterized by chaotic and radial patterns (56.7% and 28.4%, respectively; <i>p</i> < 0.001). The qualitative assessment achieved an AUC of 0.825 (95% CI: 0.780-0.871). All ULM quantitative biomarkers showed significant differences between benign and malignant lesions (all <i>p</i> < 0.05), among which maximum diameter demonstrated the highest diagnostic value (AUC = 0.898, 95% CI: 0.861-0.935). A combined quantitative biomarker (CQB) model further improved performance (AUC = 0.920). Integration of ULM qualitative and quantitative biomarkers with BI-RADS further improved diagnostic accuracy (AUC = 0.976; sensitivity 0.964; specificity 0.916) and may improve risk stratification beyond BI-RADS.</p><p><strong>Conclusion: </strong>ULM-derived qualitative and quantitative microvascular biomarkers provide complementary information beyond conventional ultrasound and may improve diagnostic performance and risk stratification in BI-RADS 4-5 breast lesions, but their role in safely reducing unnecessary biopsies requires further clinical validation.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"596312"},"PeriodicalIF":3.6,"publicationDate":"2026-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13217450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148136407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Regulatory Mechanism and Value in Early Diagnosis and Prognosis Assessment of miR-4448 in Breast Cancer.","authors":"Zhenyu Zhang, Zhengrui Liu, Chao Li, Fukai Wang, Zhaokun Tian, Xiaoyu Liu, Zhiyong Yu","doi":"10.2147/BCTT.S592003","DOIUrl":"10.2147/BCTT.S592003","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) is heterogeneous malignancy and the most common cancer among women globally. It emphasized the continuous need for effective strategies for early diagnosis and treatment. This study aimed to elucidate the regulatory mechanism of miR-4448 in BC and evaluate its value in early diagnosis and prognosis.</p><p><strong>Patients and methods: </strong>This analysis included 68 patients with BC. The expression levels of miR-4448 and thiamin pyrophosphokinase 1 (<i>TPK1</i>) were measured using RT-qPCR experiments. The diagnostic value of miR-4448 for BC was assessed via ROC analysis. The association between miR-4448 and patient survival was estimated using Multivariate Cox regression analysis and Kaplan-Meier (K-M) analysis. The effects of miR-4448 and <i>TPK1</i> on the migration, invasion and proliferation of MDA-MB-231 and MCF-7 cells were determined by CCK8 and Transwell experiments. Dual luciferase reporter assay was performed to validate <i>TPK1</i> as a direct target of miR-4448, and the correlation between their expression was confirmed by Pearson analysis.</p><p><strong>Results: </strong>Compared with the healthy controls, the level of TPK1 in the serum of BC patients was elevated, while miR-4448 levels was significantly reduced. MiR-4448 demonstrated substantial diagnostic value for BC. Low miR-4448 expression was associated with poorer survival outcomes. Inhibition of miR-4448 promoted the migration, invasion and proliferation abilities of BC cells. <i>TPK1</i> was confirmed as a direct target of miR-4448, with their expression showing a significant negative correlation. Importantly, silencing <i>TPK1</i> effectively reversed the protumorigenic effects induced by miR-4448 inhibition.</p><p><strong>Conclusion: </strong>The study identifies miR-4448 as a potential biomarker for the early diagnosis and prognosis of BC. Inhibiting miR-4448 can promote the development of BC by negatively regulating <i>TPK1</i>.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"592003"},"PeriodicalIF":3.6,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13200672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148026659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Structured Classification of Pyrotinib-Containing Neoadjuvant Regimens for HER2-Positive Breast Cancer: Efficacy, Safety, and Regimen Selection.","authors":"Jiani Liu, Xinyu Peng, Yang Yang, Xuhui Huang, Yongtao Du, Keming Liu","doi":"10.2147/BCTT.S600575","DOIUrl":"10.2147/BCTT.S600575","url":null,"abstract":"<p><p>This structured review presents a classification framework for pyrotinib-containing neoadjuvant regimens in HER2-positive breast cancer. Studies were identified through a comprehensive literature search and categorized into four strategies: pyrotinib plus chemotherapy, pyrotinib plus trastuzumab with chemotherapy, pyrotinib combined with cell-cycle inhibitors, and pyrotinib combined with antibody-drug conjugates (ADCs). We summarized the pathological complete response(pCR) rates and adverse event profiles of these approaches for neoadjuvant treatment of HER2-positive breast cancer. The pCR rates vary substantially across categories, ranging from approximately 28% to 74%, as do the grade ≥3 toxicity patterns. Therefore, the key to selecting an optimal pyrotinib-based neoadjuvant regimen is to match the regimen choice with tumor characteristics such as hormone receptor status, HER2 immunohistochemical level, intrinsic molecular subtype, and early response to initial therapy, while balancing efficacy and safety and considering patient-specific factors like age and cardiac risk. Existing studies are generally limited by small sample sizes and a lack of long-term survival data, and high-level evidence directly comparing pyrotinib-based strategies with trastuzumab plus pertuzumab is scarce. Future research should prioritize biomarker-driven patient selection, response-adaptive trial designs, and standardized toxicity management to optimize clinical decision-making.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"600575"},"PeriodicalIF":3.6,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13199712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148026616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hsa_circ_0000520 Promotes Invasion and Metastasis of Breast Cancer Cells by Targeting HSP90AA1.","authors":"Miaomiao Cai, Tao Lu, Shanmei Lv, Zhuan Zheng, Lu Gao, Huiying Wang, Xuejun Dong","doi":"10.2147/BCTT.S600770","DOIUrl":"10.2147/BCTT.S600770","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) ranks among the predominant malignancies in females globally. Growing research indicates that circular RNAs (circRNAs) exert important regulatory functions in multiple cancers. Nevertheless, the biological functions and underlying molecular mechanisms of numerous circRNAs in BC remain largely unelucidated.</p><p><strong>Methods: </strong>Firstly, based on existing database and our previous research, hsa_circ_0000520 has been found to be closely associated with BC and has potential for clinical application. Then, its circular nature was confirmed. The expression in BC cells and tumor tissues was explored by quantitative real-time polymerase chain reaction (qRT-PCR). The biological effects on BC cell growth, invasion and metastasis were verified by vitro experiments. To clarify the molecular mechanism, Chromatin Isolation by RNA Purification (ChIRP) assay coupled with mass spectrometry (MS), RNA immunoprecipitation (RIP), and Western blotting were used to identify and validate interacting proteins. Rescue experiments were conducted using the HSP90AA1 inhibitor tanespimycin. Associations between hsa_circ_0000520 expression and clinicopathological characteristics were analyzed.</p><p><strong>Results: </strong>Hsa_circ_0000520 was confirmed to be a stable circular RNA predominantly localized in the cytoplasm. Functionally, it served as an oncogene in BC and enhanced the capacities of BC cells to invade and metastasize. Mechanistically, heat shock protein 90 alpha (also termed HSP90AA1) was identified as a key interacting parter of it. Inhibition of HSP90AA1 abrogated the pro-metastatic effects of hsa_circ_0000520 but did not affect its pro-proliferative role, indicating a specific cooperation in driving invasion and metastasis. Clinically, it was significantly increased in BC cells, tumor tissues, and serum samples. Importantly, its elevated expression correlates with advanced clinical stage, specific molecular subtypes, and poor prognosis in BC patients.</p><p><strong>Conclusion: </strong>Our research results revealed an unrecognized regulatory axis, in which hsa_circ_0000520 facilitates BC cells progression by coordinating with HSP90AA1, highlighting hsa_circ_0000520 could be a promising diagnostic indicator and potential treatment target for BC.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"600770"},"PeriodicalIF":3.6,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13196807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Ultrasound and DCE-MRI Improves Accuracy in Differentiating Breast Adenosis from Carcinoma.","authors":"Yuli Zhang, Yuhong Fan, Xiaojing Yao, Haiyan Zhou, Dong Han, Yao Xiao, Peng Zhong, Jingqin Fang","doi":"10.2147/BCTT.S604929","DOIUrl":"10.2147/BCTT.S604929","url":null,"abstract":"<p><strong>Background: </strong>Discriminating breast adenosis from carcinoma remains challenging due to their overlapping imaging appearances. This study aimed to develop and validate a fusion model combining ultrasound (US) and MRI-based radiomics for improved differentiation.</p><p><strong>Methods: </strong>In this retrospective study, 260 patients (147 adenosis, 113 carcinoma) with preoperative US and MRI from March 2019 to July 2025 were enrolled and randomly split into training (n=182) and testing (n=78) cohorts at a 7:3 ratio. Radiomic features were extracted from grayscale US images depicting the largest lesion diameter and from the second-phase enhancement of DCE-MRI. After selection via maximum relevance minimum redundancy(mRMR) and Least Absolute Shrinkage and Selection Operator (LASSO) regression, radiomics models (US_Rad, MRI_Rad) were built based on selected features using the optimal algorithm among 12 candidates. A BI-RADS model based on significant US and MRI BI-RADS features was also constructed. A fusion model integrated US_Rad, MRI_Rad, BI-RADS, and age. Receiver operating characteristic (ROC) curves were used to evaluate the predictive performance of the four models.</p><p><strong>Results: </strong>In the training cohort, the area under the curve (AUC) for BI-RADS and radiomic models based on US (US_Rad) and MRI (MRI_Rad) were 0.89 (95% CI, 0.84-0.93), 0.84 (95% CI, 0.78-0.90), and 0.85 (95% CI, 0.79-0.90), respectively. In the testing cohort, the AUCs were 0.91 (95% CI, 0.83-0.97), 0.82 (95% CI, 0.73-0.91), and 0.82 (95% CI, 0.73-0.90). The fusion model achieved superior AUCs of 0.96 (95% CI, 0.94-0.98, training) and 0.97 (95% CI, 0.92-1.00, testing), significantly outperforming both the unimodal radiomic model and the BI-RADS model (all <i>p</i> < 0.01).</p><p><strong>Conclusion: </strong>Our findings suggest that the US-MRI radiomics fusion model exhibits potential in distinguishing breast adenosis from carcinoma, which may help reduce unnecessary surgeries. However, further multi-center validation is required to evaluate its generalizability before clinical application.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"604929"},"PeriodicalIF":3.6,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13182742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147970387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer.","authors":"Cheng Tian, Jihan Qiu, Yanjia Fan, Haochen Yu, Shengchun Liu","doi":"10.2147/BCTT.S595222","DOIUrl":"10.2147/BCTT.S595222","url":null,"abstract":"<p><strong>Background: </strong>Androgen receptor (AR) is widely expressed in breast cancer, but its predictive value in HER2-positive disease remains uncertain. This study evaluated the association of AR expression with neoadjuvant therapy (NAT) response and survival in HER2-positive breast cancer.</p><p><strong>Methods: </strong>We retrospectively reviewed 336 patients with primary HER2-positive breast cancer treated with NAT at the First Affiliated Hospital of Chongqing Medical University between December 2020 and July 2024. After screening, 210 patients were included. Clinicopathological characteristics, treatment response, and survival outcomes were analyzed. Factors associated with pathological complete response (pCR) and disease-free survival (DFS) were assessed using logistic regression and Cox proportional hazards models. The predictive value of AR expression, as well as AR/ER and AR/PR ratios, was also explored.</p><p><strong>Results: </strong>The overall pCR rate was 51.9% (109/210). In the overall cohort, higher AR expression was associated with pCR, but not with DFS or overall survival (OS). Multivariate analysis identified T stage, HER2 status, and AR expression as independent predictors of pCR. In exploratory subgroup analyses, the association between higher AR expression and improved treatment response was mainly observed in hormone receptor-negative/HER2-positive patients, in whom higher AR expression was associated with both a higher pCR rate and better DFS. No significant differences in treatment response or survival according to AR expression were observed in the HR+/HER2+ subgroup. Higher AR/ER and AR/PR ratios were associated with better treatment response, whereas the direct associations between AR expression and ER/PR levels appeared limited.</p><p><strong>Conclusion: </strong>Higher AR expression was associated with improved neoadjuvant treatment response in HER2-positive breast cancer, particularly in the hormone receptor-negative subgroup. However, given the retrospective single-center design and inconsistent findings in the overall population, the clinical value of AR assessment remains preliminary and requires validation in larger prospective studies.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"595222"},"PeriodicalIF":3.6,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13180362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147970354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ADPB Sensitivity in Breast Cancer is Correlated with LAT1 Expression: An in vitro Study of a Novel Theranostic Candidate.","authors":"Kharisma Perdani Kusumahstuti, Holis Abdul Holik, Muhammad Hasan Bashari, Arifudin Achmad, Shaharum Shamsuddin, Achmad Hussein Sundawa Kartamihardja","doi":"10.2147/BCTT.S564513","DOIUrl":"10.2147/BCTT.S564513","url":null,"abstract":"<p><strong>Introduction: </strong>The most common cancer in women worldwide is breast cancer. Current systemic chemotherapies do not target specific cells, which makes them toxic to normal cells. The L-type amino acid transporter 1 (LAT1) is overexpressed in a lot of cancers, also in breast cancer. Few ligand such as JPH203 (KYT-0353), a known tyrosine analogue that specifically blocks LAT1, but have limitation. It has led to efforts to create next-generation LAT1 inhibitors or prodrugs with better qualities for target therapy or diagnostic.</p><p><strong>Purpose: </strong>We investigated a new agent (S)-2-amino-4-(3,5-dichlorophenyl) butanoic acid (ADPB) as a new LAT1 inhibitor in three breast cancer cell lines: MCF-7 luminal A, HCC1954 HER2+, and MDA-MB-231 triple-negative. We hypothesized that the levels of LAT1 expression would influence the efficacy of ADPB. This could lead to a treatment that is more targeted and less harmful.</p><p><strong>Methods: </strong>We used RT-qPCR to determine the LAT1 mRNA expression in each cell line and MTT for find IC₅₀ values. These cells were given ADPB (0-160 µM) for 72 hours. There were three replication tests.</p><p><strong>Results: </strong>ADPB diminished the viability of cells in all cell lines, and the effect was dose-dependent. MDA-MB-231 was the most sensitive cell line (IC₅ ₀ = 118,1 µM 95% Cl (118,25<b>-</b>118,48), HCC-1954 was the middle-sensitive cell line (IC₅ ₀ = 126,2 µM 95% Cl (126,11<b>-</b>126,68), and MCF-7 was the least sensitive cell line (IC₅ ₀ = 127,3 µM 95% Cl (127,9<b>-</b>131,23). Study found an inverse relationship between LAT1 expression and IC₅ ₀ in all cell lines, with higher LAT1 levels correlated with lower IC₅ ₀.</p><p><strong>Conclusion: </strong>In this exploratory in vitro study, ADPB predominantly induces cytostatic effects, with cellular sensitivity associated with LAT1 expression in breast cancer cell line.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"564513"},"PeriodicalIF":3.6,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13159746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147926261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}